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The United States Food and Drug Modernization Act (FDAMA)
took effect in 1998 with high expectations from the pharmaco-
economics community. Section 114 of the Act stipulated the
conditions under which drug companies could promote health
economic information to their managed care customers, and
seemingly would make it easier for pharmacoeconomic modelers
and outcomes researchers to communicate their work. A small
survey (n = 36) of pharmaceutical and managed care representa-
tives, conducted in the months after Section 114’s enactment,
found that most respondents believed the Act would encourage
companies to present more health economic data to managed
care plans [1].
In fact, 10 years later, one hears little about Section 114. The
Food and Drug Administration (FDA) never issued guidance.
Congress never revisited the legislation. An Internet search of the
topic conﬁrms the lack of attention—symposia and articles on
the topic, circa 1999, are among the leading entries. An unsci-
entiﬁc personal survey of industry and FDA sources reinforces
the notion: Drug company economists have largely moved on;
agency ofﬁcials say that submission levels have been low under
Section 114, and that they are somewhat surprised by the trend.
What Happened?
Several theories could explain the lack of attention to Section
114.
Theory No. 1: Section 114Was Too Restrictive
The ﬁrst theory holds that rather than stimulating drug company
promotion of health-care economic information, Section 114
actually dampened enthusiasm for it.
The reason is that while Section 114 illuminated the condi-
tions under which companies could promote health economic
information—and relaxed the standard for such information
from “adequate and well-controlled trials,” to “competent and
reliable scientiﬁc evidence”—it also codiﬁed substantial restric-
tions. For one thing, the Section applies only to health economic
communications to “formulary committees or similar entities”
(as opposed to physicians or consumers). More importantly, the
Section states that health economic information provided under
Section 114 must be “directly related to a labeled indication.”
The “directly related” clause seems to restrict economic pro-
motion to end points studied in Phase III randomized clinical
trials (and then only to those that made it into the label). Indeed,
a strict reading of Section 114 suggests that it would prohibit the
use of economic models that extrapolate from surrogate end
points to longer-term outcomes, if those long-term outcomes
were not included (and did not demonstrate statistical signiﬁ-
cance) in trials. Models that extrapolate from surrogate end
points such as lipid levels to estimates of cost per life-years gained
are not permitted, unless Phase III trials of the drug under inves-
tigation demonstrated a mortality gain. Similarly, Section 114
seems to ban most cost per quality-adjusted life-year estimates,
which are based on such surrogate markers, although they are
widely recommended and used in the health economics commu-
nity, because they imply mortality gains.
In fairness, the FDA has apparently permitted some ﬂexibility
in its interpretation of Section 114’s “directly related” clause if a
drug company has established evidence from clinical trials on
“hard” surrogate end points such as cardiac events. That is,
while a drug company could not use Section 114 to make a claim
based on a modeling projection from lipid levels to cost per
QALYs, it could make such claims based on projections if it
possessed sufﬁcient evidence on the drug’s impact on myocardial
infarction or stroke (Joe Jackson, personal communication).
Section 114 would also allow cost per surrogate end point
comparisons.
The fact that FDA never released guidance on Section 114
may have made drug companies even more cautious. The uncer-
tainty surrounding what constitutes appropriate dissemination of
health economic information may have had a spillover chilling
effect on health economic promotion in medical journal adver-
tisements, which fell from 16% of all print ads in 1997 to 4% in
2002, even though print ads are not covered by Section 114 [2].
Theory No. 2:The AMCP Format Co-Opted Section 114
The second possibility is that the development of the Academy of
Managed Care Pharmacy (AMCP) Format [3] and its use by
health plans have made Section 114 much less relevant. By
calling on health plans to request that drug companies submit
dossiers that include economic information, the AMCP has
co-opted Section 114.
The Format obviates the need for Section 114 because the
FDA considers health plan appeals for information—for eco-
nomic models, for retrospective database analyses, for off-label
data, and for unpublished studies—“unsolicited requests,” which
sidestep regulatory rules governing substantiating evidence
(including those contained in Section 114). If health plans request
AMCP Format-type dossiers, drug companies are permitted great
ﬂexibility—well beyond that allowed under Section 114—to dis-
seminate pharmacoeconomic information [4]. Evidence indicates
that many health plans in the USA now use the AMCP Format or
related processes [5–7] and virtually all major manufacturers
prepare and submit these dossiers for their important drugs. The
Format is, in effect, a “safe harbor” for manufacturers for their
entire economic toolbox. As a result, Section 114 has become
something of a sideshow.
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Theory No. 3: Companies Do Use Section 114
but Quietly
A third possibility is that drug companies are, to some unknown
degree, using Section 114 to communicate health economic
information to managed care audiences. It is difﬁcult to know
the extent to which this occurs, because FDA does not require
companies to designate promotional materials submitted to the
agency as Section 114 submissions. Moreover, FDA only scruti-
nizes a small percentage of the promotional materials it receives.
Privately, drug ﬁrm and agency ofﬁcials acknowledge that
some promotional activities under Section 114 do occur. More
formal research (e.g., a survey of manufacturers about their
practices) would be useful. In theory, one could also issue a request
under the Freedom of Information Act (FOIA) for all promotional
materials submitted to FDA and sift through them to ﬁnd
examples of Section 114 cases, but it would be impractical. FDA
receives over 50,000 promotional submissions per year, and only
a tiny fraction is related to Section 114.Moreover, a telephone call
to the FOIA ofﬁce at FDA reveals that there is a several year
backlog for FOIA inquires and that bulk, unspeciﬁc requests to
their ofﬁce would not be given high priority.
What Next?
It is likely that all of the theories noted above hold some truth:
Section 114 provided a relatively minor boost to the dissemina-
tion of pharmacoeconomic data; over time, requests for eco-
nomic information via AMCP dossiers began to overshadow
Section 114; and some level of Section 114 promotion continues.
Yet another reality is that other events—from safety to compara-
tive effectiveness—have assumed greater importance since
FDAMA was enacted, and that industry and FDA have more
pressing concerns.
While Section 114 has garnered little attention, however, it
remains the law of the land. There are still instances in which
companies desire to promote health economic information pro-
actively to P&T committee members and others at health plans.
While the AMCP Format may have relegated Section 114 to a
back burner, it did not remove it entirely. Yet, 10 years after the
legislation’s enactment, what is permissible under Section 114
remains murky.
The FDA could still issue guidance on Section 114, although
the agency does not seem predisposed to do so, given its other
priorities, and the fact that there is little external pressure on the
matter. Given the increasing importance of unsolicited requests
for economic information, FDA could also issue guidance on
unsolicited requests. The agency had once promised to issue
guidance on unsolicited requests, but this too now seems
unlikely, given thorny regulatory and legal issues it raises regard-
ing free speech.
The absence of guidance leaves open questions: Where is the
“line” for Section 114 promotions? What constitutes appropriate
communication surrounding requests for AMCP-Format-type
submissions? When are requests for dossiers genuinely unso-
licited? and When is health economic information—even if
provided in response to an unsolicited request—false or mislead-
ing? A legitimate question is whether FDA guidance would help
or hinder the ﬁeld. On the one hand, guidance could clarify the
regulatory terrain. On the other, by setting down rules, it might
simply serve to further restrict useful communication.
Without formal guidance, the ﬁeld will carry on. Preferably,
FDA will interpret Section 114 as ﬂexibly as possible if challenges
arise. Ideally, the spirit behind Section 114—that business-to-
business communications about health economic data should be
permitted more latitude—will prevail. The outcomes research
community can help by continuing to monitor the ﬁeld and by
setting standards for modeling and for “real world” data [8].
Section 114 was an attempted solution to a peculiarly Ameri-
can problem. In other countries, the regulatory authorities do not
worry as much about health economic promotions to managed
care, because the “customers” in these countries are government
health ofﬁcials, who can decide for themselves what information
they would like to review. In the USA, because of the private
nature of the health system, regulations of these business com-
munications were deemed required.
A decade after its enactment, Section 114 endures but has not
fulﬁlled its promise. Even so, the ﬁeld of pharmacoeconomics has
continued to develop and even thrive. The state of the art for
modeling has advanced. Health plans are adopting the AMCP
Format (which in fact provides a better vehicle for communica-
tion than Section 114 because it empowers plans to become
active participants in debates about evidence and value). The
measurement of value is at the forefront of the US health-care
agenda. This progress has occurred despite Section 114, not
because of it.
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